Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer
Wiener klinische Wochenschrift · 2025-06 · 137 (S4) · 157-166
DOI: 10.1007/s00508-025-02544-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 04.06.2025. Verfasst von Siroos Mirzaei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine with PET Center, Clinic Ottakring, Vienna, Austria. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Lutetium, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-targeting radiopharmaceuticals for both diagnostic imaging and therapeutic applications, have become integral in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). The field has witnessed a substantial and continuously expanding body of scientific literature, encompassing case reports, original research, systematic reviews and also clinical guidelines. The objective of this joint statement is to enhance awareness of PSMA theranostics and underscore their critical role in contemporary precision oncology. We aim to provide a comprehensive yet practical perspective on the current landscape of PSMA-based diagnostic and therapeutic modalities, offering a consensus-driven approach to their clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine with PET Center, Clinic Ottakring, Vienna, Austria.
- Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria.
- Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Urology, Medical University of St. Pölten, St. Pölten, Austria.
Förderung
- Medical University of Vienna
Zitieren
APA
Mirzaei, S., Schweighofer-Zwink, G., Ofner, H., Bektic, J., Fajkovic, H., von Guggenberg, E., Ponholzer, A., Kramer, G., Lusuardi, L., Gabriel, M., Traub-Weidinger, T., Hacker, M., & Shariat, S. F. (2025). Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer. Wiener klinische Wochenschrift, 137(S4), 157-166. https://doi.org/10.1007/s00508-025-02544-4
Vancouver
Mirzaei S, Schweighofer-Zwink G, Ofner H, Bektic J, Fajkovic H, von Guggenberg E, et al. Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer. Wiener klinische Wochenschrift. 2025;137(S4):157-166. doi:10.1007/s00508-025-02544-4
BibTeX
@article{Mirzaei2025,
author = {Mirzaei, Siroos and Schweighofer-Zwink, Gregor and Ofner, Heidemarie and Bektic, Jasmin and Fajkovic, Harun and von Guggenberg, Eisabeth and Ponholzer, Anton and Kramer, Gero and Lusuardi, Lukas and Gabriel, Michael and Traub-Weidinger, Tatjana and Hacker, Marcus and Shariat, Shahrokh F},
title = {Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer},
journal = {Wiener klinische Wochenschrift},
year = {2025},
volume = {137},
number = {S4},
pages = {157--166},
doi = {10.1007/s00508-025-02544-4}
}
EUVIMED